Summarized by Masters of Longevity from PR Newswire.
This article previews a corporate press release about a pharmaceutical company's product approval and plans for commercialization in China, offering regulatory and commercial context.
Key Takeaways
- China's NMPA approved CAMCEVI 42 mg, a six-month subcutaneous leuprolide mesylate depot, for adult advanced prostate cancer treatment.
- CAMCEVI 42 mg provides a ready-to-use, sustained-release GnRH agonist formulation that reduces injection frequency compared to existing therapies.
- GenSci holds exclusive commercialization rights in China and has also submitted regulatory filings for premenopausal breast cancer for substantive NMPA review.
